Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nangibotide - Inotrem

Drug Profile

Nangibotide - Inotrem

Alternative Names: CardioTREM; LR-12; Motrem; TREM-like-transcript-1-derived-peptide

Latest Information Update: 10 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inotrem
  • Class Anti-infectives; Anti-inflammatories; Anti-ischaemics; Antivirals; Peptides
  • Mechanism of Action TREML1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Septic shock
  • Phase I Myocardial infarction

Most Recent Events

  • 08 Jan 2024 Inotrem attends End of phase II meeting with the US FDA to finalize the design of a single phase III ACCURATE trial for Nangibotide in Septic shock
  • 08 Jan 2024 Inotrem reaches agreement with the US FDA for single phase III registration (ACCURATE) trial for Nangibotide in Septic shock
  • 08 Jan 2024 Inotrem plans a phase III ACCURATE trial for Septic shock in USA, Europe and Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top